KAS
TGTX icon

Kestra Advisory Services’s TG Therapeutics TGTX Stock Holding History

Kestra Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
3,979
-2,446
-38% -$100K ﹤0.01% 3045
2026
Q1 		$213K Sell
6,425
-2,043
-24% -$60.9K ﹤0.01% 2899
2025
Q4 		$252K Sell
8,468
-1,453
-15% -$47.5K ﹤0.01% 2686
2025
Q3 		$358K Sell
9,921
-1,854
-16% -$61.1K ﹤0.01% 2301
2025
Q2 		$424K Buy
11,775
+728
+7% +$27.1K ﹤0.01% 2086
2025
Q1 		$436K Sell
11,047
-1,896
-15% -$63.8K ﹤0.01% 1906
2024
Q4 		$390K Buy
12,943
+200
+2% +$5.74K ﹤0.01% 2044
2024
Q3 		$298K Sell
12,743
-615
-5% -$13.4K ﹤0.01% 2092
2024
Q2 		$238K Sell
13,358
-9,866
-42% -$157K ﹤0.01% 2285
2024
Q1 		$353K Sell
23,224
-537
-2% -$8.55K ﹤0.01% 1889
2023
Q4 		$406K Buy
23,761
+7,419
+45% +$86.2K ﹤0.01% 1649
2023
Q3 		$137K Buy
16,342
+1,240
+8% +$17.3K ﹤0.01% 1987
2023
Q2 		$375K Sell
15,102
-4,756
-24% -$123K ﹤0.01% 1475
2023
Q1 		$299K Buy
+19,858
New +$302K ﹤0.01% 1563

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Kestra Advisory Services's TGTX Position: Q2 2026 in Review

Kestra Advisory Services reduced its TG Therapeutics (TGTX) stake by 38% in Q2 2026, selling an estimated $100K and leaving 3,979 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Kestra Advisory Services first reported a position in TGTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $436K in Q1 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Kestra Advisory Services held 3,979 shares of TG Therapeutics worth $219K as of Q2 2026.
  • Kestra Advisory Services sold 2,446 TG Therapeutics shares in Q2 2026, an estimated $100K.
  • TG Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3045 holding.
  • Kestra Advisory Services first reported a position in TG Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Kestra Advisory Services's TG Therapeutics position peaked at $436K in Q1 2025.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.